MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference - Seite 2
At Month 12, the mean percent change from baseline (%CFB) was -39.5% and -42.2% for the XQ Total Score and the Dry Mouth question of the MDASI-HN, respectively, and the mean GRCQ symptom score was 3.8. Overall, 16/24 participants reported an improvement of ≥8 points in the XQ Total Score, and 19/24 participants reported important improvements in xerostomia symptoms based on the GRCQ. The improvement reported across PRO instruments, measuring different aspects of xerostomia symptoms, provides compelling evidence of treatment effectiveness.
The mean %CFB in UWSFR at Month 12 was 112.5%, and a trend toward improved SWSFR was observed.
Conclusion
Treatment with AAV2-hAQP1 was safe and well-tolerated at all doses and resulted in meaningful improvements in xerostomia symptoms and unstimulated whole saliva flow
rate.
The presentation will be available on the Posters and Publications page of the Company’s website after the respective presentation session has concluded.
Lesen Sie auch
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with a broad pipeline of late-stage clinical programs supported by
end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well
as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially
transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch
platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially
focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel
targets, and expanding access in some of the largest disease areas where the unmet need remains great.